ASCO 2026 | Key advances in head and neck cancer from ASCO 2026
Barbara Burtness, MD, Yale School of Medicine, New Haven, CT, shares her highlights in head and neck cancer from ASCO 2026, including studies on the role of radiation in T2N0 cancers, metronomic chemotherapy with low-dose immunotherapy, and the combination of ipatasertib and pembrolizumab in the first-line. She highlights potential implications for treatment approaches in both low-resource settings and regions with widespread immunotherapy use. Dr Burtness notes that these studies raise important questions about the potential for dose de-escalation and the comparison of lesser chemotherapy regimens when combined with immunotherapy. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
